Plate Nº 81 · recorded November 18, 2026
Health & Medicine ResearchReported finding
$43 Million NIH Grant Doubles Landmark Inherited Alzheimer's Study
A $43 million NIH award will double enrollment in DIAN Obs, the WashU-led study tracking inherited Alzheimer's decades before symptoms, and fund new resilience research.
By Elena Vasquez4 min read720 words
In brief
- The National Institute on Aging awarded $43 million over five years to DIAN Obs, launched at WashU Medicine in 2008.
- The study has enrolled more than 750 people across U.S. sites and 10 other countries and will now double enrollment.
- Children of mutation carriers face a 50% inheritance risk; nearly all carriers develop dementia, often in their 40s or 50s.
- An international primary prevention trial treats people up to 25 years before expected symptom onset.
- Some participants have received amyloid immunotherapy for over 10 years as part of the study.

A five-year, $43 million award from the National Institute on Aging will let Washington University School of Medicine in St. Louis double enrollment in the world's longest-running study of inherited, early-onset Alzheimer's disease. The grant extends the Dominantly Inherited Alzheimer Network Observational Study, known as DIAN Obs, which has enrolled more than 750 people since neurologist John C. Morris launched it at WashU Medicine in 2008.
The stakes are stark. When a parent carries one of the rare gene mutations that cause Alzheimer's at a young age, each child has a 50% chance of inheriting it. Nearly everyone who does develop dementia, often in their 40s or 50s. For nearly two decades, these families have helped researchers turn that grim predictability into a roadmap of how Alzheimer's unfolds, decades before symptoms appear.
"Because these families can tell us roughly when symptoms are likely to start, we can map how the disease unfolds 20 or more years before memory fails," said Eric McDade, DO, a professor of neurology and director of the Dominantly Inherited Alzheimer Network. "And because the biology looks remarkably similar to the far more common late-onset form of Alzheimer's that emerges in older ages, what we learn here can help everyone at risk."
How does the study work?
The network is based at WashU Medicine and includes institutions across the U.S. and sites in 10 other countries. Participants who inherited the mutation, and their relatives who didn't, receive the same memory tests, brain scans, and blood and spinal fluid analyses. About three-quarters of participants had no symptoms when they joined, giving researchers a rare view of Alzheimer's silent early stages.
The observational study directly supports the Knight Family DIAN Trials Unit, which launched its first prevention clinical trial in 2012. Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology, leads the unit and directed the network before McDade. Trial participants receive the experimental drug; observational participants do not, serving as a comparison group.
"That design lets us enroll far fewer people and show regulators how a drug alters the disease's course," McDade said.
Through the trials unit, McDade is leading an international primary prevention trial — the first to treat people up to 25 years before symptoms are expected. Most participants don't yet have amyloid plaques, the clumps of toxic protein that are an early sign of Alzheimer's, in their brains. The trial is testing whether a drug that targets amyloid can keep those plaques from ever forming.
What will the new funding pay for?
Several new directions:
- Building on a recent expansion into Latin America, led by Jorge J. Llibre-Guerra, MD, associate professor of neurology and associate director of the network
- Studying people who inherited the mutation but stayed healthy long past their expected age of onset, to identify what protects them
- Tracking what happens when amyloid stays cleared from the brain for years
- Preparing for new treatments that target the genes behind the disease
- Monitoring a group of participants receiving amyloid immunotherapy — some for over 10 years — to see how treatment alters the disease course compared with its natural history
In short, the money buys both more people and new questions.
Why does it matter to families?
Marty Reiswig, 48, of Denver, has participated since 2010. He travels to St. Louis each year for testing and serves on the study's steering committee. He is also enrolled in a prevention drug trial. His father, uncle and grandfather all had early-onset Alzheimer's. He hopes his participation means his children and grandchildren won't carry that burden.
"Five more years of funding is massive," Reiswig said. "It's foundational. What a boon for people in my shoes who are looking for hope and want to be part of good science."
"My hope is that Alzheimer's will go the way of heart disease or high blood pressure, where you get your labs done, and if you're on that path, you get a drug — hopefully as simple as a pill," he added. "I don't think that's pie in the sky anymore."
The bottom line: a study built on families with rare mutations may chart the path to routine Alzheimer's prevention for everyone.
via medicine.washu.edu (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
503 articles
Nearby plates
- Common Genes Carry Nearly Triple the Alzheimer's Risk We Thought
- UK Launches £80m Challenge to Speed Up Dementia Diagnosis
- Anti-Aging Drug Boosts Brain Blood Flow in People at Higher Alzheimer's Risk
- Brain Structure Changes May Signal Alzheimer's Years Before Plaques
- Women Over 90 Face Twice the Dementia Risk of Men, Study Finds